Welcome to our dedicated page for Bitwise MARA Option Income Strategy ETF news (Ticker: IMRA), a resource for investors and traders seeking the latest updates and insights on Bitwise MARA Option Income Strategy ETF stock.
The IMRA news page on Stock Titan brings together historical and contextual information related to the IMRA ticker, which appears both as Bitwise MARA Option Income Strategy ETF and as the former Nasdaq symbol for Imara Inc. For users researching this symbol, the news record is particularly important because it documents how the biopharmaceutical business once associated with IMRA evolved through a merger into Enliven Therapeutics, Inc., now trading under the ticker ELVN.
Historical news releases describe Imara as a clinical-stage biotechnology company focused on rare inherited genetic disorders of hemoglobin and other serious diseases. These communications include updates on clinical and preclinical work with tovinontrine (IMR-687), a PDE9 inhibitor in Phase 2b trials for sickle cell disease and beta-thalassemia and in development for heart failure with preserved ejection fraction, as well as IMR-261, an oral Nrf2 activator. They also include trial readouts, interim analyses, and regulatory milestones such as FDA clearance of an investigational new drug application.
Later news items detail the merger agreement between Imara and Enliven Therapeutics, Inc., an all-stock transaction that led to the combined company being renamed Enliven Therapeutics, Inc. and trading on the Nasdaq Global Select Market under the ticker ELVN. These announcements explain that, after closing, the combined company would focus on Enliven’s precision oncology programs, including small molecule kinase inhibitors for cancer.
By reviewing the IMRA news archive, readers can trace the historical trajectory of the symbol from its use for Imara’s biotechnology activities to the merger with Enliven and the subsequent ELVN listing. This context can be useful for understanding legacy references to IMRA in older news reports and how they relate to the current Enliven Therapeutics, Inc. trading under ELVN, alongside the separate identification of IMRA as Bitwise MARA Option Income Strategy ETF.
Imara Inc. (Nasdaq: IMRA) will host a conference call and live webcast on November 5, 2020, at 8:30 a.m. ET to discuss its Q3 2020 financial results and business highlights. The company focuses on developing treatments for rare inherited genetic disorders of hemoglobin, including its lead product, IMR-687, a potential disease-modifying treatment for sickle cell disease and beta-thalassemia. Investors can access the webcast on the Imara website, and a replay will be available afterward.
Imara Inc. has commenced the Forte Phase 2b clinical trial of IMR-687 in patients with beta-thalassemia, marking a significant advancement in treatment options. This trial follows the initiation of the Ardent Phase 2b trial for sickle cell disease. The Forte trial aims to enroll about 120 adult patients, assessing the safety and effectiveness of IMR-687 in enhancing red blood cell maturation and reducing transfusion dependency. Beta-thalassemia affects approximately 288,000 individuals globally, underscoring the need for effective therapies.
BOSTON, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA) announced its participation in key virtual investor conferences this September. CEO Rahul Ballal, Ph.D., will present at the Citi 15th Annual BioPharma Virtual Conference on September 9 and 10, discussing challenges in rare disease drug development and benign hematology. Additionally, he will engage in a virtual fireside chat at the Morgan Stanley 18th Annual Global Healthcare Conference on September 17. Live webcasts will be available on Imara's website.
Imara Inc. (Nasdaq: IMRA) has received Orphan Drug designation from the European Commission for IMR-687, aimed at treating sickle cell disease (SCD). This designation highlights the critical need for effective SCD treatments, as the condition significantly impacts patients' lives. The company is advancing IMR-687 through a Phase 2b clinical trial. Orphan Drug designation provides several advantages, including market exclusivity, reduced fees, and specialized regulatory support, facilitating the development and approval process for this therapy.
Imara Inc. (Nasdaq: IMRA) has commenced Phase 2b clinical trials of IMR-687 for sickle cell disease and beta-thalassemia, with the first patient dosed in its Ardent trial. The company presented positive interim results at the European Hematology Association Congress, indicating improved outcomes with IMR-687 treatment. FDA granted multiple designations for IMR-687, enhancing its market prospects. Financially, Imara reported a net loss of $10.2 million for Q2 2020, an increase from $5.4 million year-over-year, yet its cash position stands at $106.3 million, sufficient to support operations into mid-2022.
Imara Inc. (Nasdaq: IMRA) announced the dosing of the first patient in its Ardent Phase 2b clinical trial of IMR-687 for adult sickle cell disease (SCD) patients. The trial aims to evaluate higher doses of IMR-687, specifically 300 mg and potentially 400 mg, compared to a placebo, aiming for a significant increase in fetal hemoglobin (HbF) levels. Previous interim results from a Phase 2a trial indicated well-tolerated results, showing a statistically significant increase in F-cells. Top-line data from the Phase 2a trial is expected in Q4 2020.
Imara Inc. (Nasdaq: IMRA) will host a conference call and live webcast on August 14, 2020, at 8:30 a.m. ET to discuss Q2 2020 financial results and business updates. This clinical-stage biopharmaceutical company focuses on developing therapeutics for rare genetic disorders of hemoglobin. Its lead candidate, IMR-687, is a small molecule inhibitor designed for sickle cell disease and beta-thalassemia treatment. Investors can access the webcast on the Imara website, and further details are available through investor relations contacts.
IMARA (Nasdaq: IMRA) announced that the FDA has granted Fast Track and Rare Pediatric Disease designations for its drug IMR-687, aimed at treating beta-thalassemia. These designations facilitate expedited development and review processes. IMARA recently commenced a Phase 2b clinical trial for IMR-687 in adult patients and plans to initiate pediatric testing soon. Previously, IMR-687 received Orphan Drug designation for both beta-thalassemia and sickle cell disease. These advancements underline IMARA's commitment to develop effective treatments for rare genetic disorders.
Imara Inc. (Nasdaq: IMRA) announced its addition to the U.S. small-cap Russell 2000 Index, effective July 1, 2020, following its IPO in March. This inclusion is significant as approximately $9 trillion is benchmarked against Russell U.S. Indexes, enhancing the visibility and credibility of Imara in the investment community. The company is advancing IMR-687, a treatment for blood disorders, with expectations of continued growth. Imara aims to create value for patients and shareholders through its ongoing developments in innovative therapeutics.
IMARA Inc. (Nasdaq: IMRA) announced its 'Real Impact' initiative, providing grants to community organizations addressing the needs of patients with sickle cell disease (SCD) and beta-thalassemia. Originally planning to fund 20 grants, they increased the number to 25 due to heightened demand, especially for COVID-19 relief efforts. The company assessed grant applications based on community impact and execution plans. Nineteen grants will focus on COVID-19 relief, while others support social health and organizational enhancements.
FAQ
What is the current stock price of Bitwise MARA Option Income Strategy ETF (IMRA)?
